A phase 3, multi-center trial of oral, sustained-release fampridine (4-aminopyridine) in multiple sclerosis

被引：0
|
作者：
Goodman, Andrew
Schwid, Steven
Brown, Theodore
Krupp, Lauren
Schapiro, Randall
Marinucci, Lawrence
Cohen, Ron
Blight, Andrew
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A206 / A206
页数：1
相关论文
共 50 条
  • [1] Sustained-release fampridine (4-Aminopyridine) in multiple sclerosis: Efficacy and impact on motor function
    Rabadi M.H.
    Kreymborg K.
    Vincent A.S.
    Drugs in R&D, 2013, 13 (3) : 175 - 181
  • [2] Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis
    Schwid, SR
    Petrie, MD
    McDermott, MP
    Tierney, DS
    Mason, DH
    Goodman, AD
    NEUROLOGY, 1997, 48 (04) : 817 - 821
  • [3] Sustained-release fampridine in Multiple Sclerosis
    Hadavi, S.
    Baker, M. D.
    Dobson, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (01) : 17 - 21
  • [4] Sustained-release fampridine for multiple sclerosis
    Bever, Christopher T., Jr.
    Judge, Susan I. V.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 1013 - 1024
  • [5] Dose comparison trial of sustained-release fampridine in multiple sclerosis
    Goodman, A. D.
    Brown, T. R.
    Cohen, J. A.
    Krupp, L. B.
    Schapiro, R.
    Schwid, S. R.
    Cohen, R.
    Marinucci, L. N.
    Blight, A. R.
    NEUROLOGY, 2008, 71 (15) : 1134 - 1141
  • [6] Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Goodman, Andrew D.
    Brown, Theodore R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Schwid, Steven R.
    Cohen, Ron
    Marinucci, Lawrence N.
    Blight, Andrew R.
    LANCET, 2009, 373 (9665): : 732 - 738
  • [7] Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury
    Hayes, KC
    Potter, PJ
    Hansebout, RR
    Bugaresti, TM
    Hsieh, JTC
    Nicosia, S
    Katz, MA
    Blight, AR
    Cohen, J
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (04) : 185 - 192
  • [8] Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury
    Hayes, KC
    Potter, PJ
    Hsieh, JT
    Katz, MA
    Blight, AR
    Cohen, R
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2004, 85 (01): : 29 - 34
  • [9] Sustained-release fampridine for symptomatic treatment of multiple sclerosis
    Korenke, Anne R.
    Rivey, Michael P.
    Allington, Douglas R.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1458 - 1465
  • [10] Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: a phase 3 trial
    Goodman, Andrew D.
    Schwid, Steven R.
    Brown, Theodore R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Marinucci, Lawrence N.
    Cohen, Ron
    Blight, Andrew R.
    MULTIPLE SCLEROSIS, 2008, 14 : S298 - S298
12345